Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study.

Journal Article (Journal Article)

Purpose

To test for racial differences in associations between family history (FH) of prostate cancer (PC) and prostate cancer aggressiveness in a racially diverse equal access population undergoing prostate biopsy.

Subjects/patients and methods

We prospectively enrolled men undergoing prostate biopsy at the Durham Veterans Administration from 2007 to 2018 and assigned case or control status based on biopsy results. Race and FH of PC were self-reported on questionnaires. Logistic regression was used to test the association between FH and PC diagnosis overall and by tumor aggressiveness [high- (Grade Group 3-5) or low-grade (Grade Group 1-2) vs. no cancer], overall, and stratified by race. Models were adjusted for age and year of consent, race, PSA level, digital rectal exam findings, prostate volume, and previous (negative) biopsy receipt.

Results

Of 1,225 men, 323 had a FH of PC and 652 men were diagnosed with PC on biopsy. On multivariable analysis, FH was associated with increased odds of high-grade PC in black (OR 1.85, p = 0.041) and all men (OR 1.56, p = 0.057) and was unrelated to overall or low-grade PC diagnosis, overall, or stratified by race (all p ≥ 0.325). In sensitivity analyses among men without a previous biopsy, results were slightly more pronounced.

Conclusion

In this setting of equal access to care, positive FH of PC was associated with increased tumor aggressiveness in black men, but not non-black men undergoing prostate biopsy. Further research is required to tease apart the contribution of genetics from increased PC awareness potentially influencing screening and biopsy rates in men with FH.

Full Text

Duke Authors

Cited Authors

  • Jenkins, KR; Oyekunle, T; Howard, LE; Wiggins, EK; Freedland, SJ; Allott, EH

Published Date

  • April 2021

Published In

Volume / Issue

  • 32 / 4

Start / End Page

  • 337 - 346

PubMed ID

  • 33532986

Pubmed Central ID

  • PMC7946692

Electronic International Standard Serial Number (EISSN)

  • 1573-7225

International Standard Serial Number (ISSN)

  • 0957-5243

Digital Object Identifier (DOI)

  • 10.1007/s10552-020-01389-8

Language

  • eng